Compound Evidence File
#EC-2026-0322
PMK glycidic acid (3,4-MDP-2-P methyl glycidic acid / sodium salt) CAS 1369021-80-6
Filed under Raw Materials. The bureau holds 155 laboratory returns for this compound from 46 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
46 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 13 Apr 2026 | 12 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Jan 2026 | 11 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Dec 2025 | 12 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Apr 2026 | 15 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 16 Mar 2026 | 14 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Dec 2025 | 10 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 18 May 2026 | 1 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 13 Nov 2025 | 9 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Nov 2025 | 3 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 25 Apr 2026 | 25 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 27 Feb 2026 | 4 Jul 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 13 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Jan 2026 | 28 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 9.9 | 8 Jan 2026 | 15 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Jan 2026 | 3 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 1 Nov 2025 | 27 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 15 Dec 2025 | 11 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Apr 2026 | 15 Aug 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Apr 2026 | 24 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Jan 2026 | 19 Apr 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 17 Apr 2026 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 9.9 | 9.9 | 9.9 | 20 Jun 2025 | 20 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 9.2 | 8.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 9.0 | 9.0 | 9.0 | 27 Feb 2025 | 27 Feb 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 9.0 | 9.0 | 9.0 | 9 Jun 2025 | 9 Jun 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 8.9 | 8.9 | 8.9 | 24 Apr 2025 | 24 Apr 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.5 | 7.3 | 9.4 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.3 | 7.6 | 9.4 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.2 | 6.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.0 | 7.1 | 9.0 | 21 May 2026 | 21 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 5 | 7.8 | 6.4 | 9.6 | 2 Apr 2025 | 25 May 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 3 | 7.3 | 4.8 | 10.0 | 3 Jun 2025 | 21 May 2026 |
| Peptide WorldwideCASE #VI-2026-0217 | X | 1 | 6.9 | 6.9 | 6.9 | 3 Jul 2025 | 3 Jul 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 14 | 6.4 | 3.8 | 8.0 | 2 Apr 2025 | 24 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 8 | 6.2 | 3.1 | 9.2 | 8 Jul 2025 | 24 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 1 | 6.0 | 6.0 | 6.0 | 27 Feb 2025 | 27 Feb 2025 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 5.9 | 5.9 | 5.9 | 27 Feb 2025 | 27 Feb 2025 |
| Rayshine Peptide BiochemicalsCASE #VI-2026-0545 | X | 1 | 5.7 | 5.7 | 5.7 | 17 Dec 2024 | 17 Dec 2024 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 5.1 | 5.1 | 5.1 | 21 May 2025 | 21 May 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 1 | 4.4 | 4.4 | 4.4 | 16 Mar 2025 | 16 Mar 2025 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 3.8 | 3.8 | 3.8 | 3 Jun 2025 | 3 Jun 2025 |
| Royal PeptidesCASE #VI-2026-0264 | X | 2 | 3.7 | 2.6 | 4.7 | 2 Jul 2025 | 23 May 2026 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 3.6 | 3.2 | 4.0 | 6 May 2025 | 21 May 2026 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 2.8 | 2.8 | 2.8 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for PMK glycidic acid (3,4-MDP-2-P methyl glycidic acid / sodium salt) CAS 1369021-80-6 alone.